Pharmaceuticals Sector - Solvay

12
Evolution of sales between 2000 and 2005
Group
100
90
80
70
60
50
40
30
20
10
0
Sales 2000: EUR 8 863 million
Sales 2005: EUR 8 562 million
64 %
19 %
17 %
Solvay Global Annual Report 2005
43 %
30 %
27 %
2000 2005
g Pharmaceuticals g Specialities g Essentials
Evolution of EBIT/REBIT between 2000 and 2005
Group
100
90
80
70
60
50
40
30
20
10
0
EBIT 2000: EUR 666 million
REBIT 2005: EUR 912 million
EBIT 2000 (Belgian accounting); REBIT 2005 (IFRS)
57 %
23 %
20 %
44 %
25 %
31 %
2000 2005
g Pharmaceuticals g Specialities g Essentials
Our Positions
Pharmaceuticals
Solvay is one of the world’s 40 leading
pharmaceuticals companies. It is particularly well
placed in its selected therapeutic fi elds:
– “Cardiometabolics”
– Neuroscience
– Flu vaccines
– Pancreatic enzymes
– Gastroenterology
– Hormone Therapy for Men and Women
Research and Development activities are divided
selectively between these different fi elds. In the fi rst
two we shall continue to invest in every aspect, from
research and development (R&D) through to
worldwide marketing.
Flu vaccines and pancreatic enzymes will be the
subject of targeted investments, including R&D and
licensing agreements.
Gastroenterlogy and male and female hormone
treatment will be a downstream activity, focused
on marketing.
Main products
Cardiometabolics
Europe N.America World
Cholesterol and triglycemia* 12 4 6
Fibrates*
Neuroscience
1 1 1
Antiemetics, antinauseants – 2 3
Vertigo (Menière’s syndrome)
Gastrointestinal enzymes
1 1 1
Gastrointestinal enzymes
Gastroenterology
Antispasmodics/Irritable
1 2 1
bowel syndrome medication
Hormone Therapy
1 7 2
Women’s health 2 2 2
Men’s health 3 1 1
* Including sales of TRICOR ® in the USA by Abbott.